<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00726713</url>
  </required_header>
  <id_info>
    <org_study_id>M-001</org_study_id>
    <nct_id>NCT00726713</nct_id>
  </id_info>
  <brief_title>Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)</brief_title>
  <official_title>A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pamlab, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tulane University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Omaha VA Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scott and White Hospital &amp; Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dallas Diabetes and Endocrine Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>dgd Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor Health Care System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pamlab, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if Metanx improves sensory neuropathy in
      persons with Type 2 diabetes. Metanx is a medical food available with a prescription from a
      physician. It consists of L-methylfolate, Pyridoxal 5'-phosphate, and Methylcobalamin, which
      are the active forms of folate, vitamin B6, and vitamin B12, respectively. Subjects will be
      randomly assigned to receive either Metanx or placebo for 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Vibration Perception Threshold (VPT) at 24 Weeks</measure>
    <time_frame>VPT was measured a 0 (baseline), and 24 weeks</time_frame>
    <description>Vibration Perception Threshold (VPT) 25-45 volts at hallux on either leg as measured by VPT meter on the great toe of each foot. Mean VPT averaged across both toes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neuropathy Total Symptom Score-6 (NTSS-6)</measure>
    <time_frame>NTSS-6 scores were taken at 0 (Baseline), 16, and 24 weeks</time_frame>
    <description>This measure was taken to determine if Metanx® (compared to placebo) changes neuropathic symptoms as evaluated by the Neuropathy Total Symptom Score-6 (NTSS-6)
The Neuropathy Total Symptom Score-6 Scale (NTSS-6) is a validated scale that evaluates individual neuropathy sensory symptoms in patients with diabetes mellitus (DM) and diabetic peripheral neuropathy (DPN). This scale was a modified 6 item scale that consists of yes or no questions. Scores range between 0 and 21.96, a higher score indicates greater severity of symptoms. After adjusting for baseline measurements scores are reflected as negative numbers. Negative numbers indicate improvement in symptoms. ie. a change from baseline after 24 weeks of -2 would be a greater improvement than a change in baseline of -1 after 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neuropathy Disability Score (NDS)at Week 16 and 24</measure>
    <time_frame>NDS scores were taken at 0 (Baseline), 16, and 24 weeks</time_frame>
    <description>This outcome was taken to determine if Metanx® (compared to placebo) has an effect on clinical examination as determined by the Neuropathy Disability Score (NDS)
The Neuropathy Disability Score (NDS) evaluates the severity of individual symptoms of neuropathy. A simple visual numeric distress scale is used that ranges from 0 to 10. The most favorable score is 0, which indicates an absence of symptoms. The most severe symptoms possible would be recorded as a score of 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Marker Levels of Total Folate and Total Methyl Malonic Acid (MMA) at Week 16 and 24</measure>
    <time_frame>Change from Baseline in Plasma Marker Levels at 0 (Baseline), 16, and 24 weeks</time_frame>
    <description>To determine if Metanx® (compared to placebo) affects a change in subject's total folate and total methyl malonic acid (MMA) at week 16 and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SF-36 MCS and SF-36 PCS at Week 24</measure>
    <time_frame>SF-36 MCS and SF-36 PCS scores were measured at 0 (Baseline) and 24 weeks</time_frame>
    <description>To determine if Metanx® (compared to placebo) affects a subject's &quot;quality of life&quot; as determined by the SF-36 questionnaire
The Short Form- 36 Mental Component Summary (SF-36 MCS) and SF-36 Physical Component Summary (SF-36 PCS) both measure health related quality of life, the MCS quantifying mental health and the PCS quantifying physical function. They are both scored on 100 point scales with 0 representing the worst possible outcome and 100 representing the most optimal possible scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 10-point Visual Analog Scale(VAS) at Week 24</measure>
    <time_frame>VAS scores were taken at 0 (Baseline) and 24 weeks</time_frame>
    <description>To determine if Metanx® (compared to placebo) affects a subject's lower extremity pain level using a 10-point Visual Analog Scale at Baseline and 24-week evaluation visits.
The Visual Analog Scale (VAS) measures a patients sensation of pain. A 10-cm visual analog scale is used. A measurement on the 10 cm analog scale is used to quantify the level of pain indicated with 0 cm indicating &quot;no pain&quot; and 10 cm indicating the &quot;worst pain imaginable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Exploratory) Change From Baseline in Levels of IL-6 and TNF-α, at Week 24</measure>
    <time_frame>Analyte levels were taken at 0 (Baseline) and 24 weeks</time_frame>
    <description>(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory marker levels, including IL-6 and TNF-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Exploratory) Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Question Inventory at Week 24</measure>
    <time_frame>HADS Scores scores were taken at 0 (Baseline) and 24 weeks</time_frame>
    <description>The Hospital Anxiety and Depression Scale (HADS) consists of a 14-item questionnaire that provides a measurement of depression. Each item is rated on a 4-point scale, giving a maximum scores of 21 for the most severe depression. Depression was evaluated using the Hospital Anxiety and Depression Scale (HADS) question inventory at Baseline, and 24-week evaluation visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Homocysteine at Week 16 and 24</measure>
    <time_frame>Change from Baseline in Plasma Marker Levels at 0 (Baseline), 16, and 24 weeks</time_frame>
    <description>To determine if Metanx® (compared to placebo) affects change in subjects total homocysteine levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Exploratory) Change From Baseline in Levels of Hs-CRP at Week 24</measure>
    <time_frame>Analyte levels were taken at 0 (Baseline) and 24 weeks</time_frame>
    <description>(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory markers levels including hs-CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Exploratory) Change From Baseline in Levels Potential Antioxidant (PAO) at Week 24</measure>
    <time_frame>Analyte levels were taken at 0 (Baseline) and 24 weeks</time_frame>
    <description>(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory markers levels including Potential Antioxidant (PAO)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>Type 2 Diabetic Peripheral Neuropathy (DPN)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metanx</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metanx (a medical food)</intervention_name>
    <description>Metanx one tablet twice a day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metanx placebo</intervention_name>
    <description>Metanx placebo one tablet twice a day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female between 25 and 80 years of age (inclusive);

          2. Documented diabetes mellitus Type 2 (Based upon ADA criteria);

          3. Peripheral polyneuropathy: Vibration Perception Threshold (VPT) 25-45 Volts at hallux
             on either leg.

          4. Adequate lower extremity vascular status:

               -  Palpable pedal pulse in both feet;

               -  No intermittent claudication;

               -  No history of lower extremity vascular bypass surgery or angioplasty

          5. The subject is able to understand the information in the informed consent form and is
             willing and able to sign the consent.

        Exclusion Criteria:

          1. Amputation of any kind or an ulceration within the last two (2) years including at
             Screen;

          2. History or active Charcot neuroarthropathy on either foot;

          3. Previous surgery to spine or lower extremity with residual symptoms of pain or
             difficulty with movement;

          4. Severe rheumatoid arthritis or osteoarthritis that would cause discomfort during
             causal walking or stair climbing;

          5. Current treatment with systemic steroids, immunosuppressives, or radiotherapy;

          6. Peripheral vascular disease defined as any nonpalpable foot pulse, history of
             claudication, or a history of lower extremity vascular bypass surgery or angioplasty;

          7. Glycated hemoglobin (HbA1c) &gt;9 at Screen.

          8. Uncontrolled heart (Hypertension: BP &gt; 160/90), or lung disease (uncontrolled asthma
             or shortness of breath) in the last 2 months prior to Screen;

          9. End stage kidney disorder requiring hemodialysis or serum creatinine &gt; 2.5X (normal
             upper limit);

         10. The following supplements within 2 months prior to Screen: alpha lipoic acid; B12
             injection; &gt;10mg of B6; or, &gt; 800mcg of folate;

         11. Taking either an opiate at any dose or on the maximum dose of any anticonvulsant;

         12. Pregnant or nursing;

         13. Life expectancy &lt; 12 months;

         14. Initiated therapies for Painful Diabetic Neuropathy (pregabalin, gabapentin,
             duloxetine etc.) in the last 2 months prior to Screen;

         15. Initiated new hyperglycemic, insulin, statin or hypertensive therapies within 2 months
             prior to Screen (dose modifications of current therapies are allowed at the discretion
             of the investigator);

         16. Current alcohol or drug abuse (or history of such abuse within the past 3 years); and,

         17. Not willing or able to follow procedures specified by the protocol and/or the
             instructions of the study personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivian Fonseca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham School of Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omaha VA Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes and Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>dgd Research, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Hospital &amp; Clinic</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Fonseca VA, Lavery LA, Thethi TK, Daoud Y, DeSouza C, Ovalle F, Denham DS, Bottiglieri T, Sheehan P, Rosenstock J. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med. 2013 Feb;126(2):141-9. doi: 10.1016/j.amjmed.2012.06.022. Epub 2012 Dec 5.</citation>
    <PMID>23218892</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2008</study_first_submitted>
  <study_first_submitted_qc>July 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2008</study_first_posted>
  <results_first_submitted>May 2, 2013</results_first_submitted>
  <results_first_submitted_qc>July 26, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2013</results_first_posted>
  <last_update_submitted>July 26, 2013</last_update_submitted>
  <last_update_submitted_qc>July 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metanx</keyword>
  <keyword>diabetes</keyword>
  <keyword>neuropathy</keyword>
  <keyword>folic acid</keyword>
  <keyword>folate</keyword>
  <keyword>L-methylfolate</keyword>
  <keyword>vitamin B6</keyword>
  <keyword>Pyridoxal 5'-phosphate</keyword>
  <keyword>vitamin B12</keyword>
  <keyword>methylcobalamin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of 373 patients screened, 214 entered the study , and 200 completed. The study was conducted at 6 participating U.S. sites</recruitment_details>
      <pre_assignment_details>Inclusion criteria included individuals 25 and 80 years of age, documented diabetes Type 2, Peripheral polyneuropathy, adequate lower extremity vascular status, and subject competence. 17 exclusion criteria including an HbA1c &gt;9, uncontrolled heart or lung disease, and vitamin B supplementation, contributed to the number of screening failures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metanx</title>
          <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Metanx (L-methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal-5'-phosphate 35 mg (LMF-MC-PLP)) one tablet twice a day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Placebo, one tablet twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metanx</title>
          <description>Metanx one tablet twice a day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo one tablet twice a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="106"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="214"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.29" spread="8.54"/>
                    <measurement group_id="B2" value="62.95" spread="9.17"/>
                    <measurement group_id="B3" value="62.6" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vibration Perception Threshold (VPT) at 24 Weeks</title>
        <description>Vibration Perception Threshold (VPT) 25-45 volts at hallux on either leg as measured by VPT meter on the great toe of each foot. Mean VPT averaged across both toes.</description>
        <time_frame>VPT was measured a 0 (baseline), and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metanx</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Metanx (L-methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal-5'-phosphate 35 mg (LMF-MC-PLP)) one tablet twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Placebo, one tablet twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vibration Perception Threshold (VPT) at 24 Weeks</title>
          <description>Vibration Perception Threshold (VPT) 25-45 volts at hallux on either leg as measured by VPT meter on the great toe of each foot. Mean VPT averaged across both toes.</description>
          <units>volts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.16" spread="13.00"/>
                    <measurement group_id="O2" value="33.88" spread="14.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="13.08"/>
                    <measurement group_id="O2" value="-3.27" spread="10.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Neuropathy Total Symptom Score-6 (NTSS-6)</title>
        <description>This measure was taken to determine if Metanx® (compared to placebo) changes neuropathic symptoms as evaluated by the Neuropathy Total Symptom Score-6 (NTSS-6)
The Neuropathy Total Symptom Score-6 Scale (NTSS-6) is a validated scale that evaluates individual neuropathy sensory symptoms in patients with diabetes mellitus (DM) and diabetic peripheral neuropathy (DPN). This scale was a modified 6 item scale that consists of yes or no questions. Scores range between 0 and 21.96, a higher score indicates greater severity of symptoms. After adjusting for baseline measurements scores are reflected as negative numbers. Negative numbers indicate improvement in symptoms. ie. a change from baseline after 24 weeks of -2 would be a greater improvement than a change in baseline of -1 after 24 weeks.</description>
        <time_frame>NTSS-6 scores were taken at 0 (Baseline), 16, and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metanx</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Metanx (L-methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal-5'-phosphate 35 mg (LMF-MC-PLP)) one tablet twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Placebo, one tablet twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropathy Total Symptom Score-6 (NTSS-6)</title>
          <description>This measure was taken to determine if Metanx® (compared to placebo) changes neuropathic symptoms as evaluated by the Neuropathy Total Symptom Score-6 (NTSS-6)
The Neuropathy Total Symptom Score-6 Scale (NTSS-6) is a validated scale that evaluates individual neuropathy sensory symptoms in patients with diabetes mellitus (DM) and diabetic peripheral neuropathy (DPN). This scale was a modified 6 item scale that consists of yes or no questions. Scores range between 0 and 21.96, a higher score indicates greater severity of symptoms. After adjusting for baseline measurements scores are reflected as negative numbers. Negative numbers indicate improvement in symptoms. ie. a change from baseline after 24 weeks of -2 would be a greater improvement than a change in baseline of -1 after 24 weeks.</description>
          <units>units on a scale (0-6)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" spread="1.79"/>
                    <measurement group_id="O2" value="3.45" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="1.42"/>
                    <measurement group_id="O2" value="-0.40" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="1.54"/>
                    <measurement group_id="O2" value="-0.53" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline, Week 16</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.013</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed models were used to assess baseline for continuous and discrete outcomes</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline, Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.033</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed models were used to assess baseline for continuous and discrete outcomes</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Neuropathy Disability Score (NDS)at Week 16 and 24</title>
        <description>This outcome was taken to determine if Metanx® (compared to placebo) has an effect on clinical examination as determined by the Neuropathy Disability Score (NDS)
The Neuropathy Disability Score (NDS) evaluates the severity of individual symptoms of neuropathy. A simple visual numeric distress scale is used that ranges from 0 to 10. The most favorable score is 0, which indicates an absence of symptoms. The most severe symptoms possible would be recorded as a score of 10.</description>
        <time_frame>NDS scores were taken at 0 (Baseline), 16, and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metanx</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Metanx (L-methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal-5'-phosphate 35 mg (LMF-MC-PLP)) one tablet twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Placebo, one tablet twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropathy Disability Score (NDS)at Week 16 and 24</title>
          <description>This outcome was taken to determine if Metanx® (compared to placebo) has an effect on clinical examination as determined by the Neuropathy Disability Score (NDS)
The Neuropathy Disability Score (NDS) evaluates the severity of individual symptoms of neuropathy. A simple visual numeric distress scale is used that ranges from 0 to 10. The most favorable score is 0, which indicates an absence of symptoms. The most severe symptoms possible would be recorded as a score of 10.</description>
          <units>units on a scale (0-10)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" spread="2.36"/>
                    <measurement group_id="O2" value="7.47" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="2.13"/>
                    <measurement group_id="O2" value="-0.18" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="2.11"/>
                    <measurement group_id="O2" value="-0.36" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline, Week 16</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.027</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed models were used to assess baseline for continuous and discrete outcomes</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Marker Levels of Total Folate and Total Methyl Malonic Acid (MMA) at Week 16 and 24</title>
        <description>To determine if Metanx® (compared to placebo) affects a change in subject's total folate and total methyl malonic acid (MMA) at week 16 and 24</description>
        <time_frame>Change from Baseline in Plasma Marker Levels at 0 (Baseline), 16, and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metanx</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Metanx (L-methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal-5'-phosphate 35 mg (LMF-MC-PLP)) one tablet twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Placebo, one tablet twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Marker Levels of Total Folate and Total Methyl Malonic Acid (MMA) at Week 16 and 24</title>
          <description>To determine if Metanx® (compared to placebo) affects a change in subject's total folate and total methyl malonic acid (MMA) at week 16 and 24</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Folate (nmol/L) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.19" spread="9.93"/>
                    <measurement group_id="O2" value="43.04" spread="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Folate, Change from BL Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.25" spread="10.52"/>
                    <measurement group_id="O2" value="-1.07" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Folate, Change from BL Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.53" spread="10.42"/>
                    <measurement group_id="O2" value="-2.75" spread="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total methyl malonic acid (MMA) (nmol/L) at BL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.16" spread="120.11"/>
                    <measurement group_id="O2" value="195.72" spread="169.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total MMA, Change from BL Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.38" spread="102.72"/>
                    <measurement group_id="O2" value="13.89" spread="125.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total MMA, Change from BL Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.29" spread="107.00"/>
                    <measurement group_id="O2" value="-15.42" spread="59.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Folate, Change from BL, Week 16</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.0001</p_value>
            <p_value_desc>Generalized linear mixed models were used to assess baseline for continuous and discrete outcomes</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Folate, Change from BL, Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.0001</p_value>
            <p_value_desc>Generalized linear mixed models were used to assess baseline for continuous and discrete outcomes</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total MMA, Change from Baseline Week 16</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed models were used to assess baseline for continuous and discrete outcomes</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total MMA, Change from BL, Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.0008</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed models were used to assess baseline for continuous and discrete outcomes</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Homocysteine, Change from BL, Week 16</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.0001</p_value>
            <p_value_desc>Generalized linear mixed models were used to assess baseline for continuous and discrete outcomes</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Homocysteine, Change from BL, Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed models were used to assess baseline for continuous and discrete outcomes</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SF-36 MCS and SF-36 PCS at Week 24</title>
        <description>To determine if Metanx® (compared to placebo) affects a subject’s “quality of life” as determined by the SF-36 questionnaire
The Short Form- 36 Mental Component Summary (SF-36 MCS) and SF-36 Physical Component Summary (SF-36 PCS) both measure health related quality of life, the MCS quantifying mental health and the PCS quantifying physical function. They are both scored on 100 point scales with 0 representing the worst possible outcome and 100 representing the most optimal possible scoring</description>
        <time_frame>SF-36 MCS and SF-36 PCS scores were measured at 0 (Baseline) and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metanx</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Metanx (L-methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal-5'-phosphate 35 mg (LMF-MC-PLP)) one tablet twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Placebo, one tablet twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SF-36 MCS and SF-36 PCS at Week 24</title>
          <description>To determine if Metanx® (compared to placebo) affects a subject’s “quality of life” as determined by the SF-36 questionnaire
The Short Form- 36 Mental Component Summary (SF-36 MCS) and SF-36 Physical Component Summary (SF-36 PCS) both measure health related quality of life, the MCS quantifying mental health and the PCS quantifying physical function. They are both scored on 100 point scales with 0 representing the worst possible outcome and 100 representing the most optimal possible scoring</description>
          <units>units on a scale (0-100)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 PCS, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.74" spread="10.30"/>
                    <measurement group_id="O2" value="39.03" spread="9.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 PCS, Change from BL, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="8.34"/>
                    <measurement group_id="O2" value="0.87" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 MCS, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.96" spread="9.87"/>
                    <measurement group_id="O2" value="52.66" spread="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 MCS, Change from BL, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="8.57"/>
                    <measurement group_id="O2" value="-0.29" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SF-36 MCS, Change from BL, Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.0306</p_value>
            <p_value_desc>Generalized linear mixed models were used to assess baseline for continuous and discrete outcomes</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 10-point Visual Analog Scale(VAS) at Week 24</title>
        <description>To determine if Metanx® (compared to placebo) affects a subject’s lower extremity pain level using a 10-point Visual Analog Scale at Baseline and 24-week evaluation visits.
The Visual Analog Scale (VAS) measures a patients sensation of pain. A 10-cm visual analog scale is used. A measurement on the 10 cm analog scale is used to quantify the level of pain indicated with 0 cm indicating &quot;no pain&quot; and 10 cm indicating the &quot;worst pain imaginable&quot;.</description>
        <time_frame>VAS scores were taken at 0 (Baseline) and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metanx</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Metanx (L-methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal-5'-phosphate 35 mg (LMF-MC-PLP)) one tablet twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Placebo, one tablet twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 10-point Visual Analog Scale(VAS) at Week 24</title>
          <description>To determine if Metanx® (compared to placebo) affects a subject’s lower extremity pain level using a 10-point Visual Analog Scale at Baseline and 24-week evaluation visits.
The Visual Analog Scale (VAS) measures a patients sensation of pain. A 10-cm visual analog scale is used. A measurement on the 10 cm analog scale is used to quantify the level of pain indicated with 0 cm indicating &quot;no pain&quot; and 10 cm indicating the &quot;worst pain imaginable&quot;.</description>
          <units>units on a scale (0-10)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" spread="2.77"/>
                    <measurement group_id="O2" value="3.25" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS, Change from BL, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="2.28"/>
                    <measurement group_id="O2" value="-0.03" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Exploratory) Change From Baseline in Levels of IL-6 and TNF-α, at Week 24</title>
        <description>(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory marker levels, including IL-6 and TNF-α</description>
        <time_frame>Analyte levels were taken at 0 (Baseline) and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metanx</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Metanx (L-methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal-5'-phosphate 35 mg (LMF-MC-PLP)) one tablet twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Placebo, one tablet twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>(Exploratory) Change From Baseline in Levels of IL-6 and TNF-α, at Week 24</title>
          <description>(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory marker levels, including IL-6 and TNF-α</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-6 (pg/mL), Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" spread="2.91"/>
                    <measurement group_id="O2" value="3.68" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6, Change from BL, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="2.60"/>
                    <measurement group_id="O2" value="0.07" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-a (pg/mL), Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="1.25"/>
                    <measurement group_id="O2" value="2.01" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-a, Change from BL, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.76"/>
                    <measurement group_id="O2" value="-0.04" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Exploratory) Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Question Inventory at Week 24</title>
        <description>The Hospital Anxiety and Depression Scale (HADS) consists of a 14-item questionnaire that provides a measurement of depression. Each item is rated on a 4-point scale, giving a maximum scores of 21 for the most severe depression. Depression was evaluated using the Hospital Anxiety and Depression Scale (HADS) question inventory at Baseline, and 24-week evaluation visits</description>
        <time_frame>HADS Scores scores were taken at 0 (Baseline) and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metanx</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Metanx (L-methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal-5'-phosphate 35 mg (LMF-MC-PLP)) one tablet twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Placebo, one tablet twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>(Exploratory) Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Question Inventory at Week 24</title>
          <description>The Hospital Anxiety and Depression Scale (HADS) consists of a 14-item questionnaire that provides a measurement of depression. Each item is rated on a 4-point scale, giving a maximum scores of 21 for the most severe depression. Depression was evaluated using the Hospital Anxiety and Depression Scale (HADS) question inventory at Baseline, and 24-week evaluation visits</description>
          <units>units on a scale (0-21)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HADS Depression, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="3.24"/>
                    <measurement group_id="O2" value="4.42" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HADS Depression, Change from BL, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="2.53"/>
                    <measurement group_id="O2" value="-0.45" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HADS Depression, Change from BL, Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.054</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed models were used to assess baseline for continuous and discrete outcomes</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Homocysteine at Week 16 and 24</title>
        <description>To determine if Metanx® (compared to placebo) affects change in subjects total homocysteine levels</description>
        <time_frame>Change from Baseline in Plasma Marker Levels at 0 (Baseline), 16, and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metanx</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Metanx (L-methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal-5'-phosphate 35 mg (LMF-MC-PLP)) one tablet twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Placebo, one tablet twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Homocysteine at Week 16 and 24</title>
          <description>To determine if Metanx® (compared to placebo) affects change in subjects total homocysteine levels</description>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total homocysteine (µmol/L) at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.71" spread="4.29"/>
                    <measurement group_id="O2" value="9.47" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total homocysteine, Change from BL Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.70" spread="2.90"/>
                    <measurement group_id="O2" value="0.58" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total homocysteine, Change from BL Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.68" spread="2.98"/>
                    <measurement group_id="O2" value="0.48" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Exploratory) Change From Baseline in Levels of Hs-CRP at Week 24</title>
        <description>(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory markers levels including hs-CRP</description>
        <time_frame>Analyte levels were taken at 0 (Baseline) and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metanx</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Metanx (L-methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal-5'-phosphate 35 mg (LMF-MC-PLP)) one tablet twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Placebo, one tablet twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>(Exploratory) Change From Baseline in Levels of Hs-CRP at Week 24</title>
          <description>(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory markers levels including hs-CRP</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hs-CRP (mg/L), Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.46" spread="5.98"/>
                    <measurement group_id="O2" value="7.44" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hs-CRP, Change from BL, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="4.05"/>
                    <measurement group_id="O2" value="0.13" spread="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Exploratory) Change From Baseline in Levels Potential Antioxidant (PAO) at Week 24</title>
        <description>(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory markers levels including Potential Antioxidant (PAO)</description>
        <time_frame>Analyte levels were taken at 0 (Baseline) and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metanx</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Metanx (L-methylfolate calcium 3 mg, methylcobalamin 2 mg, and pyridoxal-5'-phosphate 35 mg (LMF-MC-PLP)) one tablet twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients aged 25 to 80 years with type 2 diabetes and neuropathy, were given Placebo, one tablet twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>(Exploratory) Change From Baseline in Levels Potential Antioxidant (PAO) at Week 24</title>
          <description>(Exploratory) To determine if Metanx® affects a subject's plasma oxidative stress and inflammatory markers levels including Potential Antioxidant (PAO)</description>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PAO (µmol/L), Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1094.52" spread="230.83"/>
                    <measurement group_id="O2" value="1102.15" spread="250.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAO, Change from BL, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.95" spread="190.36"/>
                    <measurement group_id="O2" value="5.29" spread="204.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reported Adverse Events (AEs) included events starting on or after the baseline visit until 4 weeks after the last study visit on week 24. The total duration of AE monitoring was 196 days.</time_frame>
      <desc>An adverse event is any undesirable sign, symptom or medical condition occurring after starting study drug, even if the event is not considered to be related to study drug.
Adverse Event reporting was provided only with specificity to the affected Organ System. Additional detail was not available at the time of reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Metanx</title>
          <description>Metanx one tablet twice a day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo one tablet twice a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure, Congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Ligament Operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Coronary Artery Bypass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning, and procedural complications</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators agreed to delay publication of study results until after multi-center results were published or, a period of up to 20 months had elapsed after termination of the study, whichever shall occur first.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Adverse Event reporting detailed in the “Other Adverse Events” section was provided only with specificity to the affected Organ System. Additional detail for the “Other Adverse Events” was not available at the time of reporting.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Page Young, Clinical Project Manager</name_or_title>
      <organization>Pamlab Inc.</organization>
      <phone>985-867-5788</phone>
      <email>pyoung@pamlab.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

